Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 24
Polish (WIG) Biotech Industry Analysis
UpdatedMay 15, 2024
DataAggregated Company Financials
Companies13
- 7D1.4%
- 3M-2.2%
- 1Y-17.5%
- YTD-7.0%
Synthaverse is up 9.2%, leading the way for the Biotech industry, which has gained 1.4%. Meanwhile, Captor Therapeutics Spolka Akcyjna actually underperformed within the industry, shrinking 6.8% in the last week. In contrast, the industry has lost 17% in the last 12 months. As for the next few years, earnings are expected to grow by 12% per annum.
Industry Valuation and Performance
Has the Polish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 15 May 2024 | zł2.3b | zł441.3m | -zł90,006,665.00 | 57.6x | -25.4x | 5.2x |
| Fri, 12 Apr 2024 | zł2.3b | zł437.8m | -zł72,667,007.00 | 51x | -31.4x | 5.2x |
| Sun, 10 Mar 2024 | zł2.3b | zł462.1m | -zł74,341,007.00 | 60.6x | -31.1x | 5x |
| Tue, 06 Feb 2024 | zł2.4b | zł459.9m | -zł74,255,671.00 | 126.2x | -32.7x | 5.3x |
| Thu, 04 Jan 2024 | zł2.7b | zł499.9m | -zł66,755,911.00 | 89.1x | -41.1x | 5.5x |
| Sat, 02 Dec 2023 | zł2.6b | zł499.9m | -zł66,755,911.00 | 93.8x | -39.1x | 5.2x |
| Mon, 30 Oct 2023 | zł2.7b | zł518.4m | -zł60,859,678.00 | 46.3x | -44x | 5.2x |
| Wed, 27 Sep 2023 | zł2.7b | zł518.5m | -zł61,744,678.00 | 49.3x | -44x | 5.2x |
| Fri, 25 Aug 2023 | zł2.8b | zł520.3m | -zł43,292,668.00 | 50x | -64.7x | 5.4x |
| Sun, 23 Jul 2023 | zł2.9b | zł520.7m | -zł42,515,291.00 | 54.3x | -68.4x | 5.6x |
| Tue, 20 Jun 2023 | zł2.8b | zł517.3m | -zł42,548,721.00 | 63.9x | -66.6x | 5.5x |
| Thu, 18 May 2023 | zł2.9b | zł520.8m | -zł42,603,826.00 | 66x | -68.2x | 5.6x |
| Sat, 15 Apr 2023 | zł2.8b | zł492.8m | -zł18,098,449.00 | 62.1x | -157.2x | 5.8x |
| Mon, 13 Mar 2023 | zł2.8b | zł488.6m | -zł16,165,349.00 | 64.2x | -173.9x | 5.8x |
| Wed, 08 Feb 2023 | zł3.0b | zł496.5m | -zł10,783,764.00 | 48.1x | -275.6x | 6x |
| Fri, 06 Jan 2023 | zł2.9b | zł496.5m | -zł10,783,764.00 | 48.5x | -266x | 5.8x |
| Sun, 04 Dec 2022 | zł2.7b | zł457.6m | -zł19,475,709.00 | 34.5x | -140x | 6x |
| Tue, 01 Nov 2022 | zł2.6b | zł444.0m | -zł13,473,868.00 | 57.4x | -196.2x | 6x |
| Thu, 29 Sep 2022 | zł2.6b | zł401.7m | -zł21,088,868.00 | 57.4x | -121.3x | 6.4x |
| Sat, 27 Aug 2022 | zł2.9b | zł390.2m | -zł7,043,258.00 | 61.5x | -411.4x | 7.4x |
| Mon, 25 Jul 2022 | zł2.5b | zł472.9m | zł66,686.00 | 27.1x | 37861.6x | 5.3x |
| Wed, 22 Jun 2022 | zł2.3b | zł472.3m | zł5.7m | 25x | 407.9x | 4.9x |
| Fri, 20 May 2022 | zł2.6b | zł426.4m | zł11.5m | 41.8x | 225.7x | 6.1x |
| Sun, 17 Apr 2022 | zł2.7b | zł366.7m | -zł37,207,677.00 | 33.2x | -73.6x | 7.5x |
| Tue, 15 Mar 2022 | zł2.8b | zł348.8m | -zł40,884,677.00 | 31.8x | -68.8x | 8.1x |
| Thu, 10 Feb 2022 | zł3.2b | zł369.9m | -zł24,922,742.00 | 51.2x | -129.9x | 8.8x |
| Sat, 08 Jan 2022 | zł3.7b | zł369.9m | -zł24,922,742.00 | 49.2x | -146.9x | 9.9x |
| Mon, 06 Dec 2021 | zł3.7b | zł369.9m | -zł24,922,742.00 | 48.9x | -149.4x | 10.1x |
| Wed, 03 Nov 2021 | zł3.7b | zł364.5m | -zł1,455,285.00 | 32.8x | -2546.2x | 10.2x |
| Fri, 01 Oct 2021 | zł3.7b | zł364.5m | -zł1,455,285.00 | 33.3x | -2538.5x | 10.1x |
| Sun, 29 Aug 2021 | zł3.6b | zł362.9m | -zł8,912,285.00 | 39.6x | -404.9x | 9.9x |
| Mon, 05 Jul 2021 | zł3.8b | zł362.9m | -zł8,912,285.00 | 40.5x | -430.2x | 10.6x |
Price to Earnings Ratio
-550.4x
Current Industry PE
- Investors are pessimistic on the Polish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.8x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 5.8% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Polish Healthcare industry?
| PL Market | 0.91% | |
| Healthcare | 1.04% | |
| Biotech | 1.38% | |
| Biotech | 1.38% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SVE Synthaverse | zł5.22 | 11.2% +zł37.0m | -7.1% | PE77.4x | |
| MAB Mabion | zł18.20 | 10.4% +zł27.8m | 1.8% | PE7.1x | |
| BCX Bioceltix | zł66.80 | 4.4% +zł11.6m | -2.9% | PB26.4x | |
| PTG Poltreg | zł49.00 | 2.1% +zł4.7m | -4.3% | PS163.3x | |
| RDG Read-Gene | zł5.10 | 4.1% +zł2.4m | 55.5% | PS6x |
